- Report
- June 2023
- 103 Pages
Global
From €5672EUR$5,950USD£4,835GBP
- Report
- November 2023
- 168 Pages
Global
From €2383EUR$2,500USD£2,031GBP
- Report
- March 2024
- 196 Pages
Global
From €3217EUR$3,374USD£2,742GBP
€3574EUR$3,749USD£3,046GBP
- Report
- January 2024
- 200 Pages
Global
From €4767EUR$5,000USD£4,063GBP
- Report
- April 2024
- 137 Pages
Global
From €3717EUR$3,899USD£3,168GBP
- Report
- April 2024
- 180 Pages
Global
From €4671EUR$4,900USD£3,982GBP
- Report
- April 2024
- 80 Pages
United States
From €2474EUR$2,595USD£2,109GBP
- Report
- April 2024
- 100 Pages
Africa
From €3618EUR$3,795USD£3,084GBP
- Report
- February 2024
- 117 Pages
Global
From €4528EUR$4,750USD£3,860GBP
- Clinical Trials
- April 2024
- 60 Pages
Global
From €1907EUR$2,000USD£1,625GBP
- Report
- August 2023
- 255 Pages
Global
From €9057EUR$9,500USD£7,720GBP
- Report
- March 2019
- 220 Pages
Global
From €2859EUR$2,999USD£2,437GBP
- Report
- January 2021
- 420 Pages
United States
From €2269EUR$2,380USD£1,934GBP
€2669EUR$2,800USD£2,275GBP
- Report
- November 2020
- 88 Pages
Global
From €1311EUR$1,375USD£1,117GBP
€2622EUR$2,750USD£2,235GBP
- Report
- January 2023
- 125 Pages
Global
From €2374EUR$2,490USD£2,023GBP
- Report
- December 2022
- 196 Pages
Global
From €4796EUR$5,207USD£3,950GBP
- Report
- February 2023
- 244 Pages
Global
From €4004EUR$4,200USD£3,413GBP
- Report
- February 2023
- 243 Pages
Asia Pacific
From €5291EUR$5,550USD£4,510GBP
- Report
- January 2024
- 200 Pages
Japan
From €5482EUR$5,750USD£4,672GBP
- Report
- August 2022
- 119 Pages
Global
From €4290EUR$4,500USD£3,657GBP
The Alzheimer Disease Clinical Trial market is a subset of the larger Alzheimer's Disease Drugs market. It is composed of clinical trials conducted to evaluate the safety and efficacy of drugs for the treatment of Alzheimer's Disease. These trials are conducted by pharmaceutical companies, research institutions, and other organizations. The trials involve recruiting participants, administering the drug, and collecting data on the effects of the drug. The results of the trials are then used to determine whether the drug is safe and effective for treating Alzheimer's Disease.
The Alzheimer Disease Clinical Trial market is highly competitive, with many companies vying for a share of the market. Companies in the market include AbbVie, Biogen, Eli Lilly, Merck, Novartis, Pfizer, and Roche. Show Less Read more